136 related articles for article (PubMed ID: 15514570)
1. Guillain-Barré syndrome in a patient with metastatic colon cancer receiving oxaliplatin-based chemotherapy.
Christodoulou C; Anastasopoulos D; Visvikis A; Mellou S; Detsi I; Tsiakalos G; Pateli A; Klouvas G; Papadimitriou A; Skarlos DV
Anticancer Drugs; 2004 Nov; 15(10):997-9. PubMed ID: 15514570
[TBL] [Abstract][Full Text] [Related]
2. Acute inflammatory demyelinating polyradiculoneuropathy in a patient receiving oxaliplatin-based chemotherapy.
Yoon JY; Nam TS; Kim MK; Hwang JE; Shim HJ; Cho SH; Chung IJ; Bae WK
Asia Pac J Clin Oncol; 2012 Jun; 8(2):201-4. PubMed ID: 22524580
[TBL] [Abstract][Full Text] [Related]
3. Oxaliplatin-related hyperammonaemic encephalopathy in a patient with colon cancer.
Chang YY; Lin JK; Jiang JK
Colorectal Dis; 2012 Dec; 14(12):e821. PubMed ID: 22330089
[No Abstract] [Full Text] [Related]
4. [Acute idiopathic polyneuritis: a potentially fatal neuropathy that is difficult to diagnose in patients receiving oxaliplatin].
Trabut JB; Brezault C; Chaussade S; Lamarque D
Gastroenterol Clin Biol; 2007 Feb; 31(2):198-9. PubMed ID: 17347631
[No Abstract] [Full Text] [Related]
5. Oxaliplatin-related acute disseminated intravascular coagulation syndrome in a patient with metastatic colon cancer.
Malkhasyan K; Halene S; Lacy J
Clin Colorectal Cancer; 2015 Mar; 14(1):e9-e12. PubMed ID: 25446051
[No Abstract] [Full Text] [Related]
6. Dramatic tumor response of bulky liver metastases following treatment with CPT-11 and a chronomodulated 4-day infusion of 5-fluorouracil, folinic acid and oxaliplatin every 2 weeks in a colorectal cancer patient.
Gornet JM; Azoulay D; Lévi F; Yovine A; Misset JL; Goldwasser F
Anticancer Drugs; 2000 Apr; 11(4):263-8. PubMed ID: 10898541
[TBL] [Abstract][Full Text] [Related]
7. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer.
de Gramont A; Vignoud J; Tournigand C; Louvet C; André T; Varette C; Raymond E; Moreau S; Le Bail N; Krulik M
Eur J Cancer; 1997 Feb; 33(2):214-9. PubMed ID: 9135491
[TBL] [Abstract][Full Text] [Related]
8. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.
Culy CR; Clemett D; Wiseman LR
Drugs; 2000 Oct; 60(4):895-924. PubMed ID: 11085200
[TBL] [Abstract][Full Text] [Related]
9. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7.
Grothey A; Nikcevich DA; Sloan JA; Kugler JW; Silberstein PT; Dentchev T; Wender DB; Novotny PJ; Chitaley U; Alberts SR; Loprinzi CL
J Clin Oncol; 2011 Feb; 29(4):421-7. PubMed ID: 21189381
[TBL] [Abstract][Full Text] [Related]
10. A case of liver fibrosis with splenomegaly after oxaliplatin-based adjuvant chemotherapy for colon cancer.
Kang GH; Moon HS; Lee ES; Kim SH; Sung JK; Lee BS; Jeong HY; Lee HY; Kang DY
J Korean Med Sci; 2013 Dec; 28(12):1835-8. PubMed ID: 24339718
[TBL] [Abstract][Full Text] [Related]
11. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07.
Land SR; Kopec JA; Cecchini RS; Ganz PA; Wieand HS; Colangelo LH; Murphy K; Kuebler JP; Seay TE; Needles BM; Bearden JD; Colman LK; Lanier KS; Pajon ER; Cella D; Smith RE; O'Connell MJ; Costantino JP; Wolmark N
J Clin Oncol; 2007 Jun; 25(16):2205-11. PubMed ID: 17470850
[TBL] [Abstract][Full Text] [Related]
12. FDA drug approval summaries: oxaliplatin.
Ibrahim A; Hirschfeld S; Cohen MH; Griebel DJ; Williams GA; Pazdur R
Oncologist; 2004; 9(1):8-12. PubMed ID: 14755010
[TBL] [Abstract][Full Text] [Related]
13. Oxaliplatin combined to 5-fluorouracil and folinic acid: an effective therapy in patients with advanced colorectal cancer.
Gerard B; Bleiberg H; Van Daele D; Gil T; Hendlisz A; Di Leo A; Fernez B; Brienza S
Anticancer Drugs; 1998 Apr; 9(4):301-5. PubMed ID: 9635919
[TBL] [Abstract][Full Text] [Related]
14. [A case of hypersensitivity reaction to reintroduced-oxaliplatin at the second course of oxaliplatin-based chemotherapy after neoadjuvant chemotherapy for liver metastases from colon cancer].
Katayose Y; Nakagawa K; Onogawa T; Yoshida H; Motoi F; Naitoh T; Rikiyama T; Egawa S; Unno M
Gan To Kagaku Ryoho; 2011 Dec; 38(13):2651-3. PubMed ID: 22189236
[TBL] [Abstract][Full Text] [Related]
15. Delayed oxaliplatin-associated neurotoxicity following adjuvant chemotherapy for stage III colon cancer.
Choi J; Kong K; Mozaffar T; Holcombe RF
Anticancer Drugs; 2006 Jan; 17(1):103-5. PubMed ID: 16317297
[TBL] [Abstract][Full Text] [Related]
16. Management of tumour lysis syndrome during first-line palliative chemotherapy for high-volume colorectal cancer.
Gouveia HS; Lopes SO; Faria AL
BMJ Case Rep; 2018 Mar; 2018():. PubMed ID: 29545434
[TBL] [Abstract][Full Text] [Related]
17. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II study of oxaliplatin with weekly bolus fluorouracil and high-dose leucovorin (ROX) as first-line therapy for patients with colorectal cancer.
Yamada Y; Ohtsu A; Boku N; Miyata Y; Shimada Y; Doi T; Muro K; Muto M; Hamaguchi T; Mera K; Yano T; Tanigawara Y; Shirao K
Jpn J Clin Oncol; 2006 Apr; 36(4):218-23. PubMed ID: 16684860
[TBL] [Abstract][Full Text] [Related]
19. New therapeutic options in colon cancer: focus on oxaliplatin.
Wilkes GM
Clin J Oncol Nurs; 2002; 6(3):131-7. PubMed ID: 11998605
[TBL] [Abstract][Full Text] [Related]
20. Atypical presentation of acute neurotoxicity secondary to oxaliplatin.
Uña E
J Oncol Pharm Pract; 2010 Dec; 16(4):280-2. PubMed ID: 20015928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
